**Specifications Table**TableSubject areaMedicineMore specific subject areaVascular surgeryType of dataTables, figuresHow data was acquiredRetrospective analysis of patient filesData formatRaw, analyzedExperimental factorsAnkle pressure, ankle brachial indexExperimental featuresRetrospective analysis of overall mortality and freedom from cardiovascular deathData source locationTurku University Hospital, Turku, FinlandData accessibilityData is with this articleRelated research articleWickström et al. [@bib1]

**Value of the data**•Patient cohort consists of 721 patients with symptomatic lower extremity peripheral artery disease•Analysis of both symptomatic and contralateral ankle brachial index and ankle pressure in relation to patient outcome•Data may be used for assessing the role of pressure measurements with respect to patient outcome

1. Data {#s0005}
=======

The presented data is acquired from analysis of non-invasive peripheral pressure measurements of patients with clinically symptomatic (Rutherford 2--6) peripheral artery disease [@bib2], [@bib3]. [Fig. 1](#f0005){ref-type="fig"}A--D shows Kaplan-Meier curves for freedom from cardiovascular death and overall survival at defined ABI categories for both symptomatic and contralateral extremity. Corresponding Kaplan-Meier curves are presented for ankle pressure in [Fig. 2](#f0010){ref-type="fig"}A--D. Cox regression analyses with confounding factors for ABI and AP are presented in [Table 1](#t0005){ref-type="table"}.Fig. 1**A-D** Kaplan-Meier curves showing A) cumulative freedom from cardiovascular death and B) overall survival by defined ABI categories for symptomatic limb. Corresponding Kaplan-Meier curves showing C) cumulative freedom from cardiovascular death and D) overall survival for contralateral limb. Up to 7 years follow-up. Life tables for 0, 20, 40, 60 and 80 months shown in lower part of the panels. Pairwise (Wilcoxon) comparison between groups: A) ABI \< 0.25 vs. 0.25--0.89: *P* \< 0.001; vs. 0.9--1.3: *P* = 0.018; vs. \> 1.3: *P* = 0.665, ABI 0.25--0.89 vs. 0.9--1.3: *P* = 0.594; vs. \> 1.3: *P* \< 0.001, ABI 0.9--1.3 vs. \> 1.3: *P* \< 0.001 B) ABI \< 0.25 vs. 0.25--0.89: *P* \< 0.001; vs. 0.9--1.3: *P* = 0.026; vs. \> 1.3: *P* = 0.707, ABI 0.25--0.89 vs. 0.9--1.3: *P* = 0.561; vs. \> 1.3: *P* \< 0.001, ABI 0.9--1.3 vs. \> 1.3: *P* = 0.003 C) ABI \< 0.25 vs. 0.25--0.89: *P* = 0.001; vs. 0.9--1.3: *P* \< 0.001; vs. \> 1.3: *P* = 0.428, ABI 0.25--0.89 vs. 0.9--1.3: *P* = 0.174; vs. \> 1.3: *P* \< 0.001, ABI 0.9--1.3 vs. \> 1.3: *P* \< 0.001 D) ABI \< 0.25 vs. 0.25--0.89: *P* = 0.061; vs. 0.9--1.3: *P* = 0.012; vs. \> 1.3: *P* = 0.817, ABI 0.25--0.89 vs. 0.9--1.3: P = 0.061; vs. \> 1.3: *P* \< 0.001, ABI 0.9--1.3 vs. \> 1.3: *P* \< 0.001.Fig. 1Fig. 2**A-D** Kaplan-Meier curves showing A) cumulative freedom from cardiovascular death and B) overall survival by defined AP categories for symptomatic limb. Corresponding Kaplan-Meier curves showing C) cumulative freedom from cardiovascular death and D) overall survival for contralateral limb. Up to 7 years follow-up. Life tables for 0, 20, 40, 60 and 80 months shown in lower part of the panels. Pairwise (Wilcoxon) comparison between groups: A) AP (mmHg) \< 50 vs. 50--69: *P* = 0.022; vs. 70--249: *P* \< 0.001; vs. ≥ 250: *P* = 0.90, AP (mmHg) 50--69 vs. 70--249: *P* = 0.68; vs. ≥ 250: *P* = 0.014, AP (mmHg) 70--249 vs. ≥ 250: *P* \< 0.001 B) AP (mmHg) \< 50 vs. 50--69: *P* = 0.123; vs. 70--249: *P* = 0.001; vs. ≥ 250: *P* = 0.263, AP (mmHg) 50--69 vs. 70--249: *P* = 0.20; vs. ≥ 250: *P* = 0.005, AP (mmHg) 70--249 vs. ≥ 250: *P* \< 0.001 C) AP (mmHg) \< 50 vs. 50--69: *P* = 0.076; vs. 70--249: *P* \< 0.001; vs. ≥ 250: *P* = 0.995, AP (mmHg) 50--69 vs. 70--249: P = 0.63; vs. ≥ 250: *P* = 0.008, AP (mmHg) 70--249 vs. ≥ 250: *P* \< 0.001 D) AP (mmHg) \< 50 vs. 50--69: *P* = 0.466; vs. 70--249: *P* = 0.025; vs. ≥ 250: *P* = 0.332, AP (mmHg) 50--69 vs. 70--249: *P* = 0.011; vs. ≥ 250: *P* = 0.003, AP (mmHg) 70--249 vs. ≥ 250: *P* \< 0.001.Fig. 2Table 1Cox regression analysis for ABI (A) and cardiovascular and overall mortality for symptomatic and contralateral limb. Reference ABI 0.90-1.30. B) Corresponding Cox regression analysis for AP (B). Reference AP 70-250 mmHg. Confounding factors forced into Cox regression analysis were chosen according to their significance (*P* \< 0.20) in univariate analysis. CAD: coronary artery disease; HT: hypertension; DM: diabetes, ESRD: end-stage renal disease.AHR95% CI*P* value**Cardiovascular**ABI, symptomatic limbAge0.9780.965--0.992\< 0.01CAD1.451.09--1.920.01HT1.270.917--1.760,.15DM1.290.967--1.730.08ESRD1.501.01--2.340.04Statin use0.7850.585--1.050.11Smoking history0.4740.324--0.694\< 0.010.90-1.30Reference0.25-0.891.180.679--2.070.55\< 0.252.311.23--4.370.01\> 1.302.801.45--5.39\< 0.01  ABI, contralateral limbAge0.9840.971--0.9980.02CAD1.461.10--1.94\< 0.01HT1.280.926--1.770.14DM1.200.898--1.610.22ESRD1.581.05--2.370.03Statin use0.6890.511--0.9290.02Smoking history0.4940.336--0.725\< 0.010.90--1.30Reference0.25--0.891.441.03--2.020.04\< 0.252.891.92--4.340.01\> 1.303.461.63--7.34\< 0.01**Overall**ABI, symptomatic limbAge0.9780.968--0.988\< 0.01CAD1.170.937--1.480.17HT1.210.942--1.540.14DM1.070.852--1.340.56ESRD1.601.17--2.19\< 0.01Statin use0.7790.620--0.9800.03Smoking history0.5730.436--0.754\< 0.010.90--1.30Reference0.25--0.891.040.690--1.570.85\< 0.251.951.16--3.250.01\> 1.301.971.22--3.20\< 0.01  ABI, contralateral limbAge0.9810.971--0.992\< 0.01CAD1.180.950--1.480.13HT1.210.945--1.550.13DM1.030.819--1.290.81ESRD1.691.22--2.33\< 0.01Statin use0.7010.556--0.885\< 0.01Smoking history0.5790.438--0.763\< 0.010.90--1.30Reference0.25--0.891.411.09--1.820.01\< 0.252.201.06--4.570.03\> 1.302.631.91--3.63\< 0.01BHR95% CI*P* value**Cardiovascular**Ankle pressure, symptomatic limbAge0.9780.965--0.992\< 0.01CAD1.471.11--1.95\< 0.01HT1.290.931--1.790.13DM1.340.998--1.790.05ESRD1.541.03--2.290.03Statin use0.7600.567--1.020.07Smoking history0.4820.330--0.705\< 0.0170--249 mmHgReference50--69 mmhg1.631.14--2.33\< 0.01\< 50 mmHg2.181.48--3.22\< 0.01≥ 250 mmhg2.301.50--3.52\< 0.01  Ankle pressure, contralateral limbAge0.9870.973--1.000.05CAD1.351.02--1.800.04HT1.240.892--1.720.20DM1.210.901--1.620.21ESRD1.511.00--2.270.05Statin use0.6840.506--0.9240.01Smoking history0.5040.343--0.742\< 0.0170-249 mmHgReference50-69 mmhg1.630.921--2.900.09\< 50 mmhg2.931.53--5.61\< 0.01≥ 250 mmhg3.392.34--4.92\< 0.01**Overall**Ankle pressure, symptomatic limbAge0.9780.968--0.989\< 0.01CAD1.180.950--1.470.13HT1.220.955--1.570.11DM1.110.880--1.390.39ESRD1.641.20--2.25\< 0.01Statin use0.7580.603--0.9530.02Smoking history0.5740.437--0.853\< 0.0170-249 mmHgReference50-69 mmhg1.521.16--1.99\< 0.01\< 50 mmhg1.701.23--2.35\< 0.01≥ 250 mmhg2.111.49--2.97\< 0.01  Ankle pressure, contralateral limbAge0.9820.972--0.993\< 0.01CAD1.130.904--1.410.29HT1.190.923--1.530.18DM1.030.814--1.290.82ESRD1.701.23--2.35\< 0.01Statin use0.6870.543--0.870\< 0.01Smoking history0.6020.456--0.794\< 0.0170-249 mmhgReference50-69 mmhg1.820.958--3.440.07\< 50 mmhg1.831.21--2.78\< 0.01≥ 250 mmhg2.982.18--4.05\< 0.01

2. Experimental design, material*s* and methods {#s0010}
===============================================

Present data consists of peripheral pressure measurements in 721 symptomatic PAD patients admitted to the Department of Vascular Surgery at Turku University Hospital for digital subtraction angiography between January 2009 and August 2011. Dates and causes of death were collected from the Finnish national statistics registry at the end of the study period. Baseline demographics were collected from electronic patient files.

2.1. Non-invasive peripheral pressure measurements {#s0015}
--------------------------------------------------

Standardised peripheral pressure measurements were obtained in a vascular laboratory at Turku University Hospital. A Nicolet VasoGuard (Nicolet Vascular inc., Madison, WI, USA) photopletysmography (PPG) device was used for all measurements. Measurements were obtained with patients in a supine position with feet at heart level. When stable signals were obtained, brachial and ankle cuffs were inflated until disappearance of the PPG signal. Brachial and ankle pressures were determined by gradual deflation of the cuffs to the moment of reappearance of a pulsatile signal.

2.2. Statistical analysis {#s0020}
-------------------------

All statistical analyses were performed with SPSS version 22 (IBM, Armonk, NY, USA). Survival was assessed by Kaplan-Meier curves and Log-rank statistics. A Cox regression analysis was performed to assess the final predictive value of factors affecting survival. Factors with *P* \< 0.2 in Cox univariate analysis were forced into a Cox proportional hazard model to assess the risk of death.
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